18 May 2013
Keywords: amgen, aranesp, gives, response, mds, biotechnology, major
Article | 18 July 2005
US biotechnology major Amgen says that new interim data from a Phase II study evaluating the use of Aranesp (darbepoetin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 July 2005
17 May 2013
© 2013 thepharmaletter.com